Recent advances in Takayasu arteritis

International Journal of Rheumatic Diseases

Volumn 17, Issue 3, 2014, Pages 238-247

  Terao, Chikashi ^a   Yoshifuji, Hajime ^a   Mimori, Tsuneyo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical aspects; Disease aetiology and pathogenesis human; Drug treatment; Epidemiology; Genetics

Indexed keywords

C REACTIVE PROTEIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PENTRAXIN 3; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; HLA DQ ANTIGEN; HLA DRB1 ANTIGEN; HLA-DQB1 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

AORTA ARCH SYNDROME; BIOLOGICAL THERAPY; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; ERYTHROCYTE SEDIMENTATION RATE; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAGNETIC RESONANCE ANGIOGRAPHY; MEDICAL GENETICS; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; INDIA; ITALY; JAPAN; MEDICAL RESEARCH; RHEUMATOLOGY; TAKAYASU ARTERITIS; TRENDS; TURKEY;

ANIMALS; ANTIRHEUMATIC AGENTS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HLA-DQ BETA-CHAINS; HLA-DRB1 CHAINS; HUMANS; INDIA; INTERLEUKIN-12; ITALY; JAPAN; RECEPTORS, INTERLEUKIN-6; RHEUMATOLOGY; TAKAYASU ARTERITIS; TUMOR NECROSIS FACTOR-ALPHA; TURKEY;

EID: 84897025790     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12309     Document Type: Review

References (103)

1. Isobe M (2013) Takayasu arteritis revisited: current diagnosis and treatment. Int J Cardiol 168 (1), 3-10.
2. Numano F (2002) The story of Takayasu arteritisRheumatology (Oxford) 41 (1), 103-6.
3. Jennette JC, Falk RJ, Bacon PA et al. (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 (1), 1-11.
4. Dreyer L, Faurschou M, Baslund B (2011) A population-based study of Takayasu s arteritis in eastern Denmark. Clin Exp Rheumatol 29 (1 Suppl 64), S40-2.
5. Ohta A, Nagai M, Nishina M, Tomimitsu H, Kohsaka H (2013) Age at onset and gender distribution of systemic lupus erythematosus, polymyositis/dermatomyositis, and systemic sclerosis in Japan. Mod Rheumatol 23, 759-64.
6. Ishikawa K, Maetani S (1994) Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation 90, 1855-60.
7. Hata A, Noda M, Moriwaki R, Numano F (1996) Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 54(Suppl.), S155-63.
8. Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM (2008) Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118, 1276-84.
9. Arnaud L, Haroche J, Toledano D et al. (2011) Cluster analysis of arterial involvement in Takayasu arteritis reveals symmetric extension of the lesions in paired arterial beds. Arthritis Rheum 63, 1136-40.
10. Grayson PC, Maksimowicz-McKinnon K, Clark TM et al. (2012) Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis 71, 1329-34.
11. Maksimowicz-McKinnon K, Clark TM, Hoffman GS (2009) Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore) 88, 221-6.
12. Arend WP, Michel BA, Bloch DA et al. (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33, 1129-34.
13. Japanese Circulation Society (2011) Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J 75, 474-503.
14. Schmidt J, Kermani TA, Bacani AK et al. (2013) Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc 88, 822-30.
15. Umekita K, Takajo I, Miyauchi S et al. (2006) [18F]fluorodeoxyglucose positron emission tomography is a useful tool to diagnose the early stage of Takayasu's arteritis and to evaluate the activity of the disease. Mod Rheumatol 16, 243-7.
16. Andrews J, Al-Nahhas A, Pennell DJ et al. (2004) Non-invasive imaging in the diagnosis and management of Takayasu's arteritis. Ann Rheum Dis 63, 995-1000.
17. Ribbens C, Martin y Porras M, Franchimont N et al. (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61, 161-6.
18. Matsuyama A, Sakai N, Ishigami M et al. (2003) Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Circulation 108, 1469-73.
19. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G (1999) Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 100 (1, 55-60.
20. Noguchi S, Numano F, Gravanis MB, Wilcox JN (1998) Increased levels of soluble forms of adhesion molecules in Takayasu arteritis. Int J Cardiol 66(Suppl.1), S23-33; discussion S5-6.
21. Sun Y, Ma L, Yan F et al. (2012) MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu's arteritis. Int J Cardiol 156, 236-8.
22. Dagna L, Salvo F, Tiraboschi M et al. (2011) Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 155, 425-33.
23. Ishihara T, Haraguchi G, Kamiishi T, Tezuka D, Inagaki H, Isobe M (2011) Sensitive assessment of activity of Takayasu's arteritis by pentraxin3, a new biomarker. J Am Coll Cardiol 57, 1712-13.
24. Aydin SZ, Yilmaz N, Akar S et al. (2010) Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu. Rheumatology (Oxford) 49, 1889-93.
25. Misra R, Danda D, Rajappa SM et al. (2013) Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 52, 1795-801.
26. Clifford A, Hoffman GS (2014) Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol 26 (1), 7-15.
27. Nakaoka Y, Higuchi K, Arita Y et al. (2013) Tocilizumab for the treatment of patients with refractory takayasu arteritis. Int Heart J 54, 405-11.
28. Abisror N, Mekinian A, Lavigne C et al. (2013) Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 12, 1143-9.
29. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW (2000) Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 191, 303-12.
30. Ly KH, Stirnemann J, Liozon E, Michel M, Fain O, Fauchais AL (2013) Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine. doi: 10.1016/j.jbspin.2013.06.004 [Epub ahead of print]
31. Yeilding N, Szapary P, Brodmerkel C et al. (2012) Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives-an update. Ann N Y Acad Sci 1263, 1-12.
32. Sandborn WJ, Gasink C, Gao LL et al. (2012) Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367, 1519-28.
33. Mehra NK, Jaini R, Balamurugan A et al. (1998) Immunogenetic analysis of Takayasu arteritis in Indian patients. Int J Cardiol 66(Suppl.1), S127-32; discussion S33.
34. Sahin Z, Bicakcigil M, Aksu K et al. (2012) Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, Turkey. Arthritis Res Ther 14 (1), R27.
35. Vargas-Alarcon G, Flores-Dominguez C, Hernandez-Pacheco G et al. (2001) Immunogenetics and clinical aspects of Takayasu's arteritis patients in a Mexican Mestizo population. Clin Exp Rheumatol 19, 439-43.
36. Yoshida M, Kimura A, Katsuragi K, Numano F, Sasazuki T (1993) DNA typing of HLA-B gene in Takayasu's arteritis. Tissue Antigens 42, 87-90.
37. Yajima M, Numano F, Park YB, Sagar S (1994) Comparative studies of patients with Takayasu arteritis in Japan, Korea and India-comparison of clinical manifestations, angiography and HLA-B antigen. Jpn Circ J 58 (1), 9-14.
38. Terao C, Yoshifuji H, Ohmura K et al. (2013) Association of Takayasu arteritis with HLA-B 67:01 and two amino acids in HLA-B protein. Rheumatology (Oxford) 52, 1769-74.
39. Lv N, Dang A, Wang Z, Zheng D, Liu G (2011) Association of susceptibility to Takayasu arteritis in Chinese Han patients with HLA-DPB1. Hum Immunol 72, 893-6.
40. Salazar M, Varela A, Ramirez LA et al. (2000) Association of HLA-DRB1*1602 and DRB1*1001 with Takayasu arteritis in Colombian mestizos as markers of Amerindian ancestry. Int J Cardiol 75 (Suppl. 1), S113-16.
41. Saruhan-Direskeneli G, Hughes T, Aksu K et al. (2013) Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. Am J Hum Genet 93, 298-305.
42. Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A (2012) Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford) 51, 887-900.
43. Kumar P, Vahedi-Faridi A, Saenger W et al. (2009) Structural basis for T cell alloreactivity among three HLA-B14 and HLA-B27 antigens. J Biol Chem 284, 29784-97.
44. Maenaka K, Maenaka T, Tomiyama H, Takiguchi M, Stuart DI, Jones EY (2000) Nonstandard peptide binding revealed by crystal structures of HLA-B*5101 complexed with HIV immunodominant epitopes. J Immunol 165, 3260-7.
45. Appel H, Kuon W, Kuhne M et al. (2004) The solvent-inaccessible Cys67 residue of HLA-B27 contributes to T cell recognition of HLA-B27/peptide complexes. J Immunol 173, 6564-73.
46. Vargas-Alarcon G, Hernandez-Pacheco G, Soto ME et al. (2005) Comparative study of the residues 63 and 67 on the HLA-B molecule in patients with Takayasu's Arteritis. Immunol Lett 96, 225-9.
47. Kimura A, Kitamura H, Date Y, Numano F (1996) Comprehensive analysis of HLA genes in Takayasu arteritis in Japan. Int J Cardiol 54 (Suppl), S61-9.
48. Takamura C, Ohhigashi H, Ebana Y, Isobe M (2012) New human leukocyte antigen risk allele in Japanese patients with Takayasu arteritis. Circ J 76, 1697-702.
49. Jacobsen S, Baslund B, Madsen HO, Tvede N, Svejgaard A, Garred P (2002) Mannose-binding lectin variant alleles and HLA-DR4 alleles are associated with giant cell arteritis. J Rheumatol 29, 2148-53.
50. Terao C, Yoshifuji H, Kimura A et al. (2013) Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Am J Hum Genet 93, 289-97.
51. Murphy KM, Reiner SL (2002) The lineage decisions of helper T cells. Nat Rev Immunol 2, 933-44.
52. Bettelli E, Carrier Y, Gao W et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-8.
53. Kochi Y, Okada Y, Suzuki A et al. (2010) A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 42, 515-19.
54. Verma DK, Tripathy NK, Verma NS, Tiwari S (2005) Interleukin 12 in Takayasu's arteritis: plasma concentrations and relationship with disease activity. J Rheumatol 32, 2361-3.
55. Anderson CA, Boucher G, Lees CW et al. (2011) Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43, 246-52.
56. Parkes M, Barrett JC, Prescott NJ et al. (2007) Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 39, 830-2.
57. Liu H, Irwanto A, Tian H et al. (2012) Identification of IL18RAP/IL18R1 and IL12B as leprosy risk genes demonstrates shared pathogenesis between inflammation and infectious diseases. Am J Hum Genet 91, 935-41.
58. Johnston A, Xing X, Swindell WR et al. (2013) Susceptibility-associated genetic variation at IL12B enhances Th1 polarization in psoriasis. Hum Mol Genet 22, 1807-15.
59. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z (2011) Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 11 (1), 61-7.
60. Kugathasan S, Baldassano RN, Bradfield JP et al. (2008) Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet 40, 1211-15.
61. Terao C, Yoshifuji H, Kimura A et al. (2013) Two Susceptibility Loci to Takayasu Arteritis Reveal a Synergistic Role of the IL12B and HLA-B Regions in a Japanese Population. Am J Hum Genet 93, 289-97.
62. Seko Y, Minota S, Kawasaki A et al. (1994) Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis. J Clin Invest 93, 750-8.
63. Sahin N, Aksu K, Kamali S et al. (2008) PTPN22 gene polymorphism in Takayasu's arteritis. Rheumatology (Oxford) 47, 634-5.
64. Saruhan-Direskeneli G, Bicakcigil M, Yilmaz V et al. (2006) Interleukin (IL)-12, IL-2, and IL-6 gene polymorphisms in Takayasu's arteritis from Turkey. Hum Immunol 67, 735-40.
65. Direskeneli H, Tuna-Erdogan E, Gunduz F et al. (2012) PDCD1 polymorphisms are not associated with Takayasu's arteritis in Turkey. Clin Exp Rheumatol 30(1 Suppl. 70), S11-4.
66. Chen Z, Nakajima T, Inoue Y et al. (2011) A single nucleotide polymorphism in the 3'-untranslated region of MyD88 gene is associated with Buerger disease but not with Takayasu arteritis in Japanese. J Hum Genet 56, 545-7.
67. Lv N, Dang A, Zhu X et al. (2011) The role of tumor necrosis factor-alpha promoter genetic variation in Takayasu arteritis susceptibility and medical treatment. J Rheumatol 38, 2602-7.
68. Aggarwal A, Chag M, Sinha N, Naik S (1996) Takayasu's arteritis: role of Mycobacterium tuberculosis and its 65 kDa heat shock protein. Int J Cardiol 55 (1), 49-55.
69. Chauhan SK, Singh M, Nityanand S (2007) Reactivity of gamma/delta T cells to human 60-kd heat-shock protein and their cytotoxicity to aortic endothelial cells in Takayasu arteritis. Arthritis Rheum 56, 2798-802.
70. Duzova A, Turkmen O, Cinar A, Cekirge S, Saatci U, Ozen S (2000) Takayasu's arteritis and tuberculosis: a case report. Clin Rheumatol 19, 486-9.
71. Soto ME, Vargas-Alarcon G, Cicero-Sabido R, Ramirez E, Alvarez-Leon E, Reyes PA (2007) Comparison distribution of HLA-B alleles in mexican patients with takayasu arteritis and tuberculosis. Hum Immunol 68, 449-53.
72. Hong CY, Yun YS, Choi JY et al. (1992) Takayasu arteritis in Korean children: clinical report of seventy cases. Heart Vessels Suppl 7, 91-6.
73. Jain S, Kumari S, Ganguly NK, Sharma BK (1996) Current status of Takayasu arteritis in India. Int J Cardiol 54 (Suppl), S111-16.
74. Kothari SS (1995) Aetiopathogenesis of Takayasu's arteritis and BCG vaccination: the missing link? Med Hypotheses 45, 227-30.
75. Soto ME, Del Carmen A-CM, Huesca-Gomez C et al. (2012) Detection of IS6110 and HupB gene sequences of Mycobacterium tuberculosis and bovis in the aortic tissue of patients with Takayasu's arteritis. BMC Infect Dis 12, 194.
76. Zaas A, Scheel P, Venbrux A, Hellmann DB (2001) Large artery vasculitis following recombinant hepatitis B vaccination: 2 cases. J Rheumatol 28, 1116-20.
77. Eichhorn J, Sima D, Thiele B et al. (1996) Anti-endothelial cell antibodies in Takayasu arteritis. Circulation 94, 2396-401.
78. Ramot Y, Manno RA, Okazaki Y et al. (2009) Spontaneous aortitis in the Balb/c mouse. Toxicol Pathol 37, 667-71.
79. Weck KE, Dal Canto AJ, Gould JD et al. (1997) Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat Med 3, 1346-53.
80. Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P (1997) Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 65, 4832-5.
81. Bahl VK, Sengupta PP, Sathpathy G et al. (2002) Chlamydia pneumoniae infection and nonspecific aortoarteritis: search for a link with a nonatherosclerotic inflammatory arterial disease. Indian Heart J 54, 46-9.
82. Cooper AM, Magram J, Ferrante J, Orme IM (1997) Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J Exp Med 186 (1), 39-45.
83. Gerber SA, Moran JP, Frelinger JG, Frelinger JA, Fenton BM, Lord EM (2003) Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Br J Cancer 88, 1453-61.
84. Sorensen EW, Gerber SA, Frelinger JG, Lord EM (2010) IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol 184, 1858-66.
85. Matias MA, Saunus JM, Ivanovski S, Walsh LJ, Farah CS (2011) Accelerated wound healing phenotype in Interleukin 12/23 deficient mice. J Inflamm (Lond) 8, 39.
86. Kaczorowski CC, Stodola TJ, Hoffmann BR et al. (2013) Targeting the endothelial progenitor cell surface proteome to identify novel mechanisms that mediate angiogenic efficacy in a rodent model of vascular disease. Physiol Genomics 45, 999-1011.
87. Hotchi M (1992) Pathological studies on Takayasu arteritis. Heart Vessels Suppl 7, 11-17.
88. Wagner AD, Bjornsson J, Bartley GB, Goronzy JJ, Weyand CM (1996) Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am J Pathol 148, 1925-33.
89. Sneller MC (2002) Granuloma formation, implications for the pathogenesis of vasculitis. Cleve Clin J Med 69(Suppl.2), SII40-3.
90. Weyand CM, Goronzy JJ (2003) Medium- and large-vessel vasculitis. N Engl J Med 349, 160-9.
91. Sagar S, Ganguly NK, Koicha M, Sharma BK (1992) Immunopathogenesis of Takayasu arteritis. Heart Vessels Suppl 7, 85-90.
92. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM (2010) Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 121, 906-15.
93. Terrier B, Geri G, Chaara W et al. (2012) Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 64, 2001-11.
94. Piggott K, Deng J, Warrington K et al. (2011) Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation 123, 309-18.
95. Dhingra R, Talwar KK, Chopra P, Kumar R (1993) An enzyme linked immunosorbent assay for detection of anti-aorta antibodies in Takayasu arteritis patients. Int J Cardiol 40, 237-42.
96. Wang H, Ma J, Wu Q, Luo X, Chen Z, Kou L (2011) Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. J Vasc Surg 53 (1), 174-80.
97. Florey OJ, Johns M, Esho OO, Mason JC, Haskard DO (2007) Antiendothelial cell antibodies mediate enhanced leukocyte adhesion to cytokine-activated endothelial cells through a novel mechanism requiring cooperation between Fc{gamma}RIIa and CXCR1/2. Blood 109, 3881-9.
98. Chauhan SK, Tripathy NK, Nityanand S (2006) Antigenic targets and pathogenicity of anti-aortic endothelial cell antibodies in Takayasu arteritis. Arthritis Rheum 54, 2326-33.
99. Tobon GJ, Alard JE, Youinou P, Jamin C (2009) Are autoantibodies triggering endothelial cell apoptosis really pathogenic? Autoimmun Rev 8, 605-10.
100. Misra R, Aggarwal A, Chag M, Sinha N, Shrivastava S (1994) Raised anticardiolipin antibodies in Takayasu's arteritis. Lancet 343, 1644-5.
101. Shibata H, Yasunami M, Obuchi N et al. (2006) Direct determination of single nucleotide polymorphism haplotype of NFKBIL1 promoter polymorphism by DNA conformation analysis and its application to association study of chronic inflammatory diseases. Hum Immunol 67, 363-73.
102. Kimura A, Ota M, Katsuyama Y et al. (2000) Mapping of the HLA-linked genes controlling the susceptibility to Takayasu's arteritis. Int J Cardiol 75(Suppl.1), S105-10; discussion S11-2.
103. Kimura A, Kobayashi Y, Takahashi M et al. (1998) MICA gene polymorphism in Takayasu's arteritis and Buerger's disease. Int J Cardiol 66(Suppl.1), S107-13; discussion S15.